The departure of the CMO is a routine organizational change for a biotech at this stage. Monitor for the appointment of a successor and any potential impact on clinical development timelines, but no immediate trading action is warranted.
Price Chart
Executive Summary
Parabilis Medicines disclosed the mutually agreed departure of Chief Medical Officer Fawzi Benzaghou, M.D., effective September 30, 2026. He will receive severance per his employment agreement. This is a routine C-suite transition with no replacement named, and no financial details or red flags are present in the filing.
Key Facts
- Chief Medical Officer Fawzi Benzaghou, M.D., departing by mutual agreement effective September 30, 2026.
- Dr. Benzaghou will receive severance benefits per his existing employment agreement.
- No replacement has been named in the filing.
- No financial figures, guidance, or material operational changes were disclosed.
Financial Impact
No financial impact disclosed; severance is contractual and routine.
Risk Factors
- Potential temporary gap in clinical development leadership if a successor is not named promptly.
- Risk of broader management turnover if this departure signals internal discord, though the 'mutual agreement' language is standard.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-380171 |
| Document: 0001193125-26-380171-index-headers.html | 0001193125-26-380171 |
| Document: 0001193125-26-380171-index.html | 0001193125-26-380171 |
| Document: 0001193125-26-380171.txt | 0001193125-26-380171 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 2d ago | Press Release | $24.79 | awaiting T+60 | — | $24.44 (−1.41%) |
Oct 19, 2026 7d ago | Press Release | $25.35 | awaiting T+60 | — | $24.44 (−3.59%) |
Sep 15, 2026 5w ago | 8-K | $36.88 | awaiting T+60 | — | $24.44 (−33.73%) |
Sep 2, 2026 7w ago | 8-K | $40.75 | awaiting T+60 | — | $24.44 (−40.02%) |
Aug 13, 2026 10w ago | 8-K | $35.67 | awaiting T+60 | — | $24.44 (−31.48%) |
Aug 13, 2026 10w ago | Press Release | $35.67 | awaiting T+60 | — | $24.44 (−31.48%) |
Jul 22, 2026 13w ago | Insider Buy | $32.81 $22.75 | ▼ −30.66% | ▼ −34.31% | $24.44 (−25.51%) |
Jun 29, 2026 17w ago | Insider Cluster | $29.19 $33.31 | ▲ +14.11% | ▲ +10.50% | $24.44 (−16.27%) |
Jun 16, 2026 18w ago | Insider Cluster | $26.03 $36.16 | ▲ +38.92% | ▲ +36.23% | $24.44 (−6.11%) |
Jun 15, 2026 19w ago | Insider Cluster | $26.59 $36.88 | ▲ +38.70% | ▲ +36.84% | $24.44 (−8.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers